NCT00090701View on ClinicalTrials.gov

A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

September 30, 2004

Conditions

Lung Neoplasms

Interventions

DRUG

AG2037

Trial Locations (4)

10021

Pfizer Investigational Site, New York

20007

Pfizer Investigational Site, Washington D.C.

33612

Pfizer Investigational Site, Tampa

92064

Pfizer Investigational Site, Poway

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY